Overview

• In Cell Reports Medicine, researchers report a lipid nanoparticle platform that co-delivers antigen with two immune-boosting adjuvants to heighten anti-tumor responses.
• A peptide-based regimen left 80% of vaccinated mice tumor-free for the full 250-day study in a melanoma challenge, whereas controls died within about five weeks.
• Using tumor lysate, vaccinated mice rejected cancers across models, with tumor-free rates of 88% for pancreatic, 75% for triple-negative breast and 69% for melanoma.
• In metastasis-style lung challenge tests, none of the vaccinated mice developed lung tumors while all comparison mice did.
• The team says the approach may support preventive and therapeutic uses and has launched NanoVax Therapeutics to pursue translation, but no human trials have begun.